OncoGenex to Present at the UBS Global Specialty Pharmaceuticals Conference

BOTHELL, WA, and VANCOUVER, May 17 /PRNewswire/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that Cameron Lawrence, OncoGenex' Director of Finance and Principal Accounting Officer, will be presenting at the UBS Global Specialty Pharmaceuticals Conference on Wednesday, May 25 at 10:00 a.m. BST (5:00 a.m. ET). The conference takes place at the UBS offices in London.

The live audio webcast can be accessed through the Investor Relations page of the OncoGenex website at www.oncogenex.com. A webcast replay will be available approximately one hour after the live webcast concludes and will be archived for 90 days.

About OncoGenex

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development.  OncoGenex and Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) have entered a global collaboration and license agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer. The companies plan to begin Phase 3 development of custirsen in first-line treatment of advanced, unresectable non-small cell lung cancer in 2011. OGX-427 is in Phase 2 clinical development; and CSP-9222 and OGX-225 are currently in pre-clinical development.

More information about OncoGenex is available at www.oncogenex.com.

SOURCE OncoGenex Pharmaceuticals, Inc.

Suggested Articles

Combining inhibitors of KRAS-G12C, mTOR and IGF1R can significantly shrink lung tumors in mice and human cancer cells, a study found.

X4 Pharmaceuticals has a new R&D chief: Renato Skerlj, who founded the company alongside CEO Paula Ragan and biotech luminary Henri Termeer.

Henlius Biotech missed the $477 million goal it set for its IPO, but still made the top five biopharma IPOs this year with its $410 million listing.